Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15587783 | 0.83 | POLB (0.64) | POLBALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL17896337 | 0.81 | MAP4K4 (0.54) | POLBALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL18626609 | 0.80 | POLB (0.60) | POLBALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL17896328 | 0.80 | MAP4K4 (0.52) | POLBALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL17896325 | 0.80 | MAP4K4 (0.48) | RAB9ALMNAMEN1KMT2AMAP4K4 | |
| SCHEMBL18626608 | 0.72 | L3MBTL1 (0.50) | HPGDRAB9AMEN1KMT2AMAP4K4 | |
| SCHEMBL15886278 | 0.72 | POLB (0.67) | POLBALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL21282782 | 0.72 | GAA (0.51) | POLBALDH1A1KDM4ELMNAMEN1 | |
| SCHEMBL15587329 | 0.69 | HPGD (0.64) | POLBALDH1A1HPGDKDM4ERAB9A | |
| SCHEMBL21348452 | 0.68 | JAK2 (0.53) | ALDH1A1HPGDKDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | POLB 1063/4885ALDH1A1 534/4885HPGD 703/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | POLB 1697/4885ALDH1A1 586/4885HPGD 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.